Hilary Kramer has 30 years of experience on Wall Street; she was an analyst and investment banker at...
LifeLock: Invest in Fraud Protection
02/03/2015 8:00 am EST
This featured recommendation is a leading provider of proactive identity theft protection services for consumers, and fraud and risk solutions for enterprises, explains Jim Oberweis, Jr., small-cap expert and editor of The Oberweis Report.
Lifelock (LOCK) protects its members by constantly monitoring identity-related events, such as new account openings and credit-related applications.
If the company detects that a member’s personally identifiable information is being used, they offer notifications and alerts that allow members to confirm valid or unauthorized identity use.
Enterprise customers utilize this information in real time to reduce financial losses from identity fraud. LifeLock offers its consumer services on a monthly or annual subscription basis.
As of September 30, 2014, the company served about 3.5 million members, up 23% year over year, and average monthly revenue per member was $11.22, up 7% year over year. The customer retention rate was 87.5% during the most recent quarter.
LifeLock also serves more than 250 enterprise customers, including six of the top ten US financial institutions, five of the top six US wireless service providers, and eight of the top ten US credit card issuers.
In the company’s latest reported third quarter, sales increased approximately 29% to $123.0 million from $95.7 million in the third quarter of last year.
LifeLock reported earnings per share of $.16 in the latest reported third quarter versus $.12 in the same quarter of last year.
Clients of Oberweis Asset Management own approximately 33,200 shares. These shares may be appropriate for risk-oriented investors.
More from MoneyShow.com:
Related Articles on STOCKS
The primary objective of our research offering is to help investors cut through the myriad of noise ...
Emerson Electric Co. (EMR) was established in 1890 in St. Louis, Missouri; its primary products incl...
Ionis (IONS) and their partner Biogen (BIIB) recently announced strong 3Q results for Spinraza sales...